melrilimab
human monoclonal immunoglobulin G2 (IgG2) sigma antibody that binds domain 1 of the cell surface IL‐33R
Also Known As:
CNTO-7160; CNTO7160; GSK-3772847; GSK3772847
Networked: 2
relevant articles (1 outcomes,
2 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Asthma (Bronchial Asthma)
11/01/2022
- " Treatment with GSK3772847 may be beneficial for patients with uncontrolled asthma. " 01/01/2023
- " Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial." 11/01/2022
- " At week 16, 56 participants (81%) and 45 (66%) receiving placebo and GSK3772847, respectively, had loss of asthma control (an 18% reduction [95% credible interval = 2%-35%]). " 11/01/2022
- " The primary end point was loss of asthma control; secondary end points were the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of GSK3772847. " 11/01/2022
- " Early loss of asthma control prevented full analysis of the secondary efficacy end points after week 4. The most frequent classes of treatment-related adverse events were cardiac disorders (n = 3 [4%] in both groups) and musculoskeletal/connective tissue disorders (with GSK3772847, n = 3 [4%]; with placebo n = 0). "
|
2. | Heart Diseases (Heart Disease)
|
|
Related Drugs and Biologics